<DOC>
	<DOCNO>NCT01952249</DOCNO>
	<brief_summary>This Phase 1b/2 study paclitaxel plus demcizumab subject platinum resistant ovarian , primary peritoneal fallopian tube cancer .</brief_summary>
	<brief_title>A Study Demcizumab Plus Paclitaxel Subjects With Platinum Resistant Ovarian</brief_title>
	<detailed_description>Subjects must receive prior weekly paclitaxel 3 prior chemotherapy regimens Phase 1b portion study 2 prior chemotherapy regimens Phase 2 portion study . Prior enrollment , subject undergo screen determine study eligibility . In Phase 1b portion study , 3 subject treat dose level dose-limiting toxicity ( DLTs ) observe . If 1 3 subject experience DLT , dose level expand 6 subject . If 2 subject experience DLT , subject dose level 3 additional subject add precede dose cohort unless 6 subject already treat dose level . Subjects assess DLTs Days 0-28 . Dose escalation newly enrol subject , appropriate , occur subject cohort complete Day 28 DLT assessment . After final patient Phase 1b portion trial complete Day 28 DLT assessment , 50 subject enrol Phase 2 portion study treat demcizumab high dose level &lt; 2 DLTs 6 subject .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Subjects must cytologically histologically confirm ovarian , primary peritoneal fallopian tube cancer.. In addition , subject must tumor least 1 cm single dimension radiographically apparent CT , PETCT MRI ( i.e. , RECIST version 1.1 measurable disease ) . 2 . Subjects must platinum resistant disease ( i.e. , define disease progression le 6 month receive minimum 4 cycle platinum contain regimen ) . 3 . Subjects follow histologic epithelial cell type eligible : Serous adenocarcinoma , endometrioid adenocarcinoma , mucinous adenocarcinoma , undifferentiated carcinoma , clear cell adenocarcinoma , mixed epithelial carcinoma , transitional cell carcinoma , malignant Brenner 's Tumor , adenocarcinoma N.O.S . 4 . Age &gt; 21 year 5 . ECOG performance status &lt; 3 1 . Subjects receive investigational medicinal product anticancer therapy . 2 . Prior therapy weekly paclitaxel recurrent disease ( administration weekly paclitaxel part upfront treatment strategy acceptable long patient progress receive weekly paclitaxel recur within 4 month receive weekly paclitaxel ) 3 . Nonepithelial ovarian carcinoma , include malignant mixed Mullerian tumor . 4 . For Phase 1b portion study , 3 prior chemotherapy regimens Phase 2 portion study 2 prior chemotherapy regimen . Maintenance therapy follow induction chemotherapy count separate regimen . In addition , hormonal therapy ( e.g. , tamoxifen aromatase inhibitor ) count separate regimen . 5 . Prior radiotherapy pelvis abdomen 6 . Subjects receive heparin , warfarin , similar anticoagulant . Note : Subjects may receive lowdose aspirin and/or nonsteroidal antiinflammatory agent .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Ovarian</keyword>
	<keyword>Primary Peritoneal</keyword>
	<keyword>Fallopian Tube Cancer</keyword>
</DOC>